ArticleACS nano2009
Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle.
Article in ACS nano, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 242 citations in OpenAlex.
- Progress in Optical Methods for the Detection of Two Core Blood Biomarkers of Alzheimer's Disease: Amyloid-Beta and Tau Proteins.Biosensors · 2026Review
- Advances in Gold Nanoparticles for the Diagnosis and Management of Alzheimer's Disease.Pharmaceutics · 2025Review
- Tau-targeting nanoparticles for treatment of Alzheimer's disease.Exploration (Beijing, China) · 2025Review
- Extreme Tolerance of Nanoparticle-Protein Corona to Ultra-High Abundance Proteins Enhances the Depth of Serum Proteomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Biotechnological advances in microbial synthesis of gold nanoparticles: Optimizations and applications.3 Biotech · 2024Review
- Symmetry-breaking-induced off-resonance second-harmonic generation enhancement in asymmetric plasmonic nanoparticle dimers.Nanophotonics (Berlin, Germany) · 2024Article
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.Journal of nanobiotechnology · 2024Review
- Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy.CNS & neurological disorders drug targets · 2024Review
- Review
- Role of lysosome in healing neurological disorders by nano-bioengineering.Frontiers in neuroscience · 2023Review
- Article
- Enhanced Thermo-optical Response by Means of Anapole Excitation.The journal of physical chemistry letters · 2022Article
- Article
- Nanomedicine: A Promising Way to Manage Alzheimer's Disease.Frontiers in bioengineering and biotechnology · 2021Review
- Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The Implication of Nanotechnology.International journal of molecular sciences · 2020Review
- The detection and identification of dengue virus serotypes with quantum dot and AuNP regulated localized surface plasmon resonance.Nanoscale advances · 2020Article
- Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019Review
- Improving Sensitivity and Specificity of Amyloid-β Peptides and Tau Protein Detection with Antibiofouling Magnetic Nanoparticles for Liquid Biopsy of Alzheimer's Disease.ACS biomaterials science & engineering · 2019Article
- Controlled fluorescence quenching by antibody-conjugated graphene oxide to measure tau protein.Royal Society open science · 2018Article
- Nanomedicine applications in women's health: state of the art.International journal of nanomedicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a progressive mental disorder disease, which affects 26.6 million people worldwide and estimated increments can be 100 millions by 2050. Since there is no cure at present, early diagnosis of AD is crucial for the current drug treatments. Driven by the need, here we demonstrate for the first time that monoclonal anti-tau antibody-coated gold nanoparticle based two-photon scattering assay can be used for the detection of Alzheimer's tau protein in the 1 pg/mL level which is about 2 orders of magnitude lower than cutoff values (195 pg/mL) for tau protein in CSF (cerebrospinal fluid). We have shown that when anti-tau antibody-coated gold nanoparticles were mixed with 20 ng/mL of tau protein, two-photon Rayleigh scattering intensity (TPRS) increases by about 16 times. The mechanism of TPRS intensity change has been discussed. Our data demonstrated that our TPRS assay is highly sensitive to tau protein and it can distinguish from BSA, which is one of the most abundant protein components in CSF. Our results demonstrate the potential for a broad application of this type of nanobionanotechnology in practical biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.